103 Views

Aeglea Biotherapeutics snags $44 mln Series B

Aeglea Biotherapeutics Inc, a biopharmaceutical company focused on treating tumor metabolism, has raised $44 million in Series B funding. Return backers Lilly Ventures and Novartis Venture Fund led the round with participation from other investors that included UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.

Aduro Biotech nets $51.4 mln Series D

Berkeley, Calif.-based immuno-oncology firm Aduro Biotech has received $51.4 million in Series D financing. The investors included OrbiMed, Janus Capital Management, Franklin Advisers and Foresite Capital Management. Leerink Partners served as placement agent.

166 Views

Flex Pharma raises $40 mln from big investor group

Flex Pharma, a biopharmaceutical company focused on treatments for neuromuscular disorders, has raised $40 million from an investor group. Investors include Longwood Fund, Bessemer Venture Partners, EcoR1 Capital, Jennison Associates, Lightstone Ventures, Alexandria Equities, CD-Venture, Bindley Capital Partners, City Hill Ventures and several individuals including Steve Pagliuca, managing director at Bain Capital.

114 Views

Bellicum Pharmaceuticals nabs $55 mln Series C

Bellicum Pharmaceuticals has closed $55 million in Series C funding. The investors included funds managed by RA Capital Management, Perceptive Advisors, Jennison Associates (on behalf of certain clients), Sabby Capital and Ridgeback Capital Management. Jefferies was the placement agent. Based in Houston, Bellicum Pharmaceuticals is a biotech firm focused on developing cellular immunotherapies.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget